1.02
-0.02(-1.92%)
Currency In USD
Address
15 Independence Blvd
Warren, NJ 07059
United States of America
Phone
877 838 6436
Website
Sector
Healthcare
Industry
Biotechnology
Employees
18
First IPO Date
January 05, 2022
| Name | Title | Pay | Year Born |
| Dr. Ryan H. Saadi M.D., M.P.H, M.P.H. | Co-Founder, Chief Executive Officer & Chairperson | 501,000 | 1965 |
| Mr. Kirti Desai CPA | Chief Financial Officer | 300,000 | 1957 |
| Dr. Neal Flomenberg M.D. | Chief Scientific Officer and Global R&D Lead | 350,000 | 1954 |
| Mr. Tapan V. Shah | Head of Investor Relations & Corporate Development | 0 | N/A |
| Mr. Stephen Chen M.B.A. | Chief Technical Officer | 0 | N/A |
| Mr. Mittul Mehta | Chief Information Officer & Head of Tevogen.ai | 0 | N/A |
| Mr. Sadiq Khan M.B.A. | Chief Commercial Officer | 0 | 1962 |
| Mr. David E. Banko CPA | Global Head of Government Affairs & Patient Access | 0 | N/A |
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.